Bibliographic record
Abstract
Updates from the Annual Session17 October 2000Update in OncologyLynn M. Schuchter, MD and Daniel G. Haller, MDLynn M. Schuchter, MDFrom University of Pennsylvania, Philadelphia, Pennsylvania.Search for more papers by this author and Daniel G. Haller, MDFrom University of Pennsylvania, Philadelphia, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-8-200010170-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Many important papers in the field of oncology were published in 1999, but we limited our selection for this Update to studies of fairly common types of cancer. We concentrated on studies of breast cancer, cervical cancer, multiple myeloma, colorectal cancer, and prostate cancer.Breast CancerThe three articles on breast cancer presented here were among the most important articles on the topic published in 1999. The first discussed the role of prophylactic mastectomy in women who are at increased risk for breast cancer, the next examined the use of tamoxifen to prevent breast cancer, and the third evaluated the ...References1. Eisen A, Weber BL. Prophylactic mastectomy—the price of fear. N Engl J Med. 1999;340:137-8. CrossrefMedlineGoogle Scholar2. Slamon D, Leyland-Jones B, Shak S, et al . Addition of Herceptin to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized multinational controlled phase III trial [Abstract]. Proc Am Soc Clin Oncol. 1998;17:98a. Google Scholar3. . Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst. 1997;89:497-505. CrossrefMedlineGoogle Scholar4. Myers RP, Larson-Keller JJ, Bergstralh EJ, Zincke H, Oesterling JE, Lieber MM. Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer: results of long-term followup. J Urol. 1992;147:910-5. CrossrefMedlineGoogle Scholar5. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al . Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-64. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From University of Pennsylvania, Philadelphia, Pennsylvania.Corresponding Author: Lynn M. Schuchter, MD, University of Pennsylvania Cancer Center, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104; e-mail, [email protected]med.upenn.edu.Current Author Addresses: Dr. Schuchter: University of Pennsylvania Cancer Center, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104.Dr. Haller: Hospital of the University of Pennsylvania, 3400 Spruce Street, 16 Penn Tower, Philadelphia, PA 19104. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByUpdate in Women's HealthJudith M.E. Walsh, MD, MPH, Nancy C. Dolan, MD, and Pamela Charney, MD 17 October 2000Volume 133, Issue 8Page: 615-621KeywordsAdenomasAdjuvant chemotherapyBreast cancerCancer treatmentCervical cancerChemotherapyColorectal cancerProstate cancerQuality of lifeRadiation therapy ePublished: 17 October 2000 Issue Published: 17 October 2000 CopyrightCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.012 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.006 | 0.004 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.005 | 0.004 |
| Open science | 0.002 | 0.002 |
| Research integrity | 0.004 | 0.004 |
| Insufficient payload (model declined to judge) | 0.252 | 0.154 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".